33.55
0.39%
-0.1945
Supernus Pharmaceuticals Inc stock is currently priced at $33.55, with a 24-hour trading volume of 49,769.
It has seen a -0.39% decreased in the last 24 hours and a +8.14% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $33.38 pivot point. If it approaches the $34.19 resistance level, significant changes may occur.
Supernus Pharmaceuticals Inc Stock (SUPN) Financials Data
Supernus Pharmaceuticals Inc (SUPN) Revenue 2023
SUPN reported a revenue (TTM) of $607.52 million for the quarter ending December 31, 2023, a -8.95% decline year-over-year.
Supernus Pharmaceuticals Inc (SUPN) Net Income 2023
SUPN net income (TTM) was $1.32 million for the quarter ending December 31, 2023, a -97.83% decrease year-over-year.
Supernus Pharmaceuticals Inc (SUPN) Cash Flow 2023
SUPN recorded a free cash flow (TTM) of $110.53 million for the quarter ending December 31, 2023, a -5.05% decrease year-over-year.
Supernus Pharmaceuticals Inc (SUPN) Earnings per Share 2023
SUPN earnings per share (TTM) was -$0.0026 for the quarter ending December 31, 2023, a -100.25% decline year-over-year.
Supernus Pharmaceuticals Inc Stock (SUPN) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 21 '24 |
Sale |
35.31 |
14,491 |
511,677 |
8,570 |
Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 20 '24 |
Option Exercise |
25.30 |
400 |
10,120 |
8,970 |
Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 20 '24 |
Sale |
35.31 |
400 |
14,124 |
8,570 |
Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 19 '24 |
Option Exercise |
25.30 |
12,364 |
312,809 |
20,934 |
Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 19 '24 |
Sale |
35.31 |
12,364 |
436,573 |
8,570 |
Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 13 '24 |
Option Exercise |
17.61 |
62,366 |
1,098,523 |
44,686 |
Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 13 '24 |
Sale |
33.74 |
62,366 |
2,104,289 |
8,570 |
Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 12 '24 |
Option Exercise |
12.98 |
3,884 |
50,414 |
12,454 |
Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 12 '24 |
Sale |
32.99 |
3,884 |
128,133 |
8,570 |
Khattar Jack A. | President, CEO |
Feb 28 '24 |
Option Exercise |
0.00 |
35,000 |
0 |
932,005 |
Supernus Pharmaceuticals Inc Stock (SUPN) Latest News
Supernus to Participate in Two Upcoming Investor Conferences
GlobeNewswire Inc.
Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference
GlobeNewswire Inc.
Supernus (SUPN) Reports Q4 Earnings: What Key Metrics Have to Say
Zacks Investment Research
Supernus Pharmaceuticals (SUPN) Lags Q4 Earnings Estimates
Zacks Investment Research
Supernus Announces Fourth Quarter and Full Year 2023 Financial Results
GlobeNewswire Inc.
Ahead of Supernus (SUPN) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Zacks Investment Research
About Supernus Pharmaceuticals Inc
Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy. The company's product candidates comprise SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder (ADHD); and SPN-812, a viloxazine hydrochloride, which is in Phase III clinical trial that is used for the treatment of ADHD. It also develops SPN-809, a viloxazine hydrochloride, which is in Phase II ready clinical trial for the treatment of depression. The company markets its products through wholesalers and pharmaceutical distributors. Supernus Pharmaceuticals, Inc. was founded in 2005 and is based in Rockville, Maryland.
Cap:
|
Volume (24h):